Abstract
A single 400-mg oral dose of grepafloxacin (OPC-17116) was given to each of six healthy male volunteers, and the concentrations of the drug in plasma, cantharides-induced inflammatory fluid, and urine were measured over the subsequent 12 h. The mean peak concentration in plasma of 1.5 micrograms/ml was attained at a mean time of 2.0 h postdose. The mean peak concentration in inflammatory fluid of 1.1 micrograms/ml was attained at a mean time of 4.8 h postdose. The mean elimination half-life in plasma was 5.2 h, and that in inflammatory fluid was 12.7 h. The overall penetration into inflammatory fluid was 180.6% (or 133% if one aberrant result from one volunteer is excluded). Recovery of the drug in urine during the first 24 h postdose was 8.3% of the administered dose. Our results indicate that a once- or twice-daily dosage of grepafloxacin should be adequate to treat systemic infections caused by most bacterial pathogens.
Full Text
The Full Text of this article is available as a PDF (171.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bennett J. V., Brodie J. L., Benner E. J., Kirby W. M. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966 Mar;14(2):170–177. doi: 10.1128/am.14.2.170-177.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bergan T., Thorsteinsson S. B., Solberg R., Bjornskau L., Kolstad I. M., Johnsen S. Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. Am J Med. 1987 Apr 27;82(4A):97–102. [PubMed] [Google Scholar]
- Gomeni R. PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation. Comput Biol Med. 1984;14(1):25–34. doi: 10.1016/0010-4825(84)90017-9. [DOI] [PubMed] [Google Scholar]
- Imada T., Miyazaki S., Nishida M., Yamaguchi K., Goto S. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrob Agents Chemother. 1992 Mar;36(3):573–579. doi: 10.1128/aac.36.3.573. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Johnson J. H., Cooper M. A., Andrews J. M., Wise R. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother. 1992 Nov;36(11):2444–2446. doi: 10.1128/aac.36.11.2444. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neu H. C., Fang W., Gu J. W., Chin N. X. In vitro activity of OPC-17116. Antimicrob Agents Chemother. 1992 Jun;36(6):1310–1315. doi: 10.1128/aac.36.6.1310. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sader H. S., Erwin M. E., Jones R. N. In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones. Eur J Clin Microbiol Infect Dis. 1992 Apr;11(4):372–381. doi: 10.1007/BF01962081. [DOI] [PubMed] [Google Scholar]
- Stone J. W., Andrews J. M., Ashby J. P., Griggs D., Wise R. Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother. 1988 Oct;32(10):1508–1510. doi: 10.1128/aac.32.10.1508. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Verho M., Malerczyk V., Dagrosa E., Korn A. Dose linearity and other pharmacokinetics of ofloxacin: a new, broad-spectrum antimicrobial agent. Pharmatherapeutica. 1985;4(6):376–382. [PubMed] [Google Scholar]
- Wise R., Andrews J. M., Brenwald N. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone. J Antimicrob Chemother. 1993 Apr;31(4):497–504. doi: 10.1093/jac/31.4.497. [DOI] [PubMed] [Google Scholar]
- Wise R., Gillett A. P., Cadge B., Durham S. R., Baker S. The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. J Infect Dis. 1980 Jul;142(1):77–82. doi: 10.1093/infdis/142.1.77. [DOI] [PubMed] [Google Scholar]